Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder

• Status: Completed
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study's primary aim is to compare time to relapse and relapse rates in responders to acute escitalopram who are then randomized to placebo versus continuation treatment with escitalopram.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborators: National Institute of Mental Health (NIMH); Rhode Island Hospital
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Outpatient men and women age 18 and older

• Diagnosis of BDD within 6 months of study start date based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)

• Score of 24 or higher on the BDD-Yale-Brown Obsessive Compulsive Scale

• Lives within driving distance of Boston, MA or Providence, RI

Exclusion Criteria:

• Suicidal or homicidal tendencies

• Alcohol/drug abuse or dependence within 3 months of study entry